Menu Search
Equities

Protagonist Therapeutics Inc

PGF:BER

Protagonist Therapeutics Inc

Actions
  • Price (EUR)40.40
  • Today's Change0.20 / 0.50%
  • Shares traded36.00
  • 1 Year change+165.79%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 08:50 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its lead clinical asset, rusfertide (PTG-300), is an injectable hepcidin mimetic in development for the potential treatment of polycythemia vera (PV) and other blood disorders. The Company’s Interleukin-23 receptor (IL-23R) antagonist compound JNJ-2113 is an orally delivered investigational drug that is designed to block biological pathways targeted by marketed injectable antibody drugs. Its PN-943 is a wholly owned investigational orally delivered gut-restricted alpha 4 beta 7 (α4β7) specific integrin antagonist for inflammatory bowel disease (IBD).

  • Revenue in USD (TTM)323.80m
  • Net income in USD170.85m
  • Incorporated2006
  • Employees126.00
  • Location
    Protagonist Therapeutics Inc7707 Gateway Blvd Ste 140NEWARK 94560-1160United StatesUSA
  • Phone+1 (510) 474-0170
  • Fax+1 (302) 636-5454
  • Websitehttps://www.protagonist-inc.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.